ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectively

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) today announced financial results and business highlights for the fourth quarter and year ended December 31, 2025. The company reported record quarterly and full year net revenues, driven by strong performance in its Rare Disease and Generics businesses. ANI also reaffirmed its 2026 financial guidance, expecting to deliver over $1 billion in revenue with its Rare Disease segment representing approximately 60% of total revenue.

Why it matters

ANI's strong financial results and growth in its Rare Disease business demonstrate the company's successful transformation into a leading rare disease pharmaceutical company. The company's focus on developing and commercializing innovative therapies in specialty indications like ophthalmology, rheumatology, and neurology has positioned it for continued success.

The details

Key highlights include record quarterly and full year net revenues for the Rare Disease segment, driven by strong growth in Cortrophin Gel and ILUVIEN. The company also saw robust performance in its Generics business, with net revenues increasing 28.2% in Q4 and 27.6% for the full year. ANI plans to further expand its Rare Disease sales force in 2026 to capture the opportunity in acute gouty arthritis flares, where Cortrophin Gel is the only approved ACTH therapy.

  • On July 4, Quinn allegedly dove onto the hood of a Waymo vehicle and covered sensors.
  • On July 29, Quinn allegedly damaged a Waymo's tires and driver's side mirror.
  • On August 11, Quinn allegedly stomped on a windshield while someone was inside.

The players

ANI Pharmaceuticals, Inc.

An American biopharmaceutical company committed to developing, manufacturing, and commercializing innovative and high-quality therapeutics, with a focus on its Rare Disease, Generics, and Brands businesses.

Nikhil Lalwani

President and CEO of ANI Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“'2025 was a year of significant growth for our Rare Disease and Generics businesses, which drove expansion to both our top- and bottom-line,'”

— Nikhil Lalwani, President and CEO of ANI Pharmaceuticals (Globe Newswire)

“'We see a significant multi-year growth opportunity for Cortrophin Gel as we expand in underpenetrated specialty indications and launch a dedicated organization for acute gouty arthritis flares. With a proven track record, we expect to deliver more than $1 billion in revenue in 2026, with Rare Disease representing approximately 60% of total revenue, while continuing to fulfill our purpose of Serving Patients, Improving Lives.'”

— Nikhil Lalwani, President and CEO of ANI Pharmaceuticals (Globe Newswire)

The takeaway

ANI's strong financial performance and strategic focus on its Rare Disease business positions the company for continued growth and success as it transforms into a leading rare disease pharmaceutical company. The company's commitment to developing innovative therapies and expanding its commercial capabilities in specialty indications bodes well for its future.